PU-H71 Effectively Induces Degradation of IκB Kinase β in the Presence of TNF-α
Overview
Authors
Affiliations
This study is to determine if PU-H71, a heat shock protein inhibitor, induces killing of malignant breast cells together with treatment of tumor necrosis factor-α (TNF-α). The related molecular mechanisms were also studied. A primary mammary epithelial cell line HMEC2595 cells and the highly metastatic breast cell line MDA-MB-231, the HER2-positive BT-474 cells, and the ER-positive MCF7 cells were treated with PU-H71 in the presence or absence of TNF-α. The effects of PU-H71 and TNF-α treatments on cells viabilities and on intracellular signaling pathway proteins were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, apoptosis assays, immunoblot assays, and luciferase assays. It was found that TNF-α enhances the toxic effects of PU-H71 on tumor cells but not normal cells. PU-H71 treatments lead to degradation of IKKβ. Moreover, PU-H71 down-regulates the NF-κB transcriptional activity induced by TNF-α treatment. The experimental results indicated PU-H71 effectively induces cell killing of malignant breast cells in the presence of TNF-α, possibly through a mechanism related to degradation of IKKβ. It is suggested that combination of PU-H71 and TNF-α treatments might be an effective therapeutic strategy of breast malignancies.
Kale S, Korcum A, Dundar E, Erin N Naunyn Schmiedebergs Arch Pharmacol. 2019; 393(2):253-262.
PMID: 31522240 DOI: 10.1007/s00210-019-01725-z.
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
Speranza G, Anderson L, Chen A, Do K, Eugeni M, Weil M Invest New Drugs. 2017; 36(2):230-239.
PMID: 28808818 PMC: 6126370. DOI: 10.1007/s10637-017-0495-3.
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
Goldstein R, Yang S, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K J Clin Invest. 2015; 125(12):4559-71.
PMID: 26529251 PMC: 4665772. DOI: 10.1172/JCI80714.